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Assessing patient-reported quality of life outcomes in vulva cancer patients – a systematic literature 
review 
 
Abstract  
Objectives 
 Vulva cancer (VC) treatment carries a high risk of severe late effects that may have a negative impact on 
Quality of Life (QoL). Patient-reported outcome measures (PROMs) are increasingly used when evaluating 
disease- and treatment-specific effects. However, the adequacy of measures used to assess sequelae and 
QoL in VC remain unclear. The aim of the present study was to evaluate disease- and treatment- related 
effects as measured by PROMs in VC patients and to identify available VC- specific PROMs. 
Methods/Materials  
A systematic literature search from 1990 to 2016 was performed. The inclusion criterion was report of 
disease- and treatment-related effects in VC patients using PROMs in the assessment. Methodological and 
reporting quality was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement. This systematic review was performed as part of Phase one of the 
development of a European Organisation for Research and Treatment of Cancer QoL questionnaire for VC 
patients. 
Results  
The search revealed 2299 relevant hits, with 11 papers extracted including a total of 535 women with VC; 
no randomized controlled trials were identified. The selected studies exhibited great heterogeneity in 
terms of PROMs use. Twenty-one different instruments assessed QoL. Most of the questionnaires were 
generic.  Different issues (sexuality, lymphedema, body image, urinary and bowel function, vulva-specific 
symptoms) were reported as potentially important but the results were not systematically collected. Only 
one VC-specific questionnaire was identified but did not allow assessment and reporting on scale level. 
Conclusions  
Vulva cancer treatment is associated with considerable morbidity deteriorating QoL. To date there is no 
validated PROM available that provides adequate coverage of VC-related issues. The study confirms the 
need for a VC-specific QoL instrument with sensitive scales that allows broad cross-cultural application for 
use in clinical trials.  
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Highlights 
    
 Vulva cancer treatment is associated with considerable morbidity 
 Data on PROMs after treatment of vulva cancer are scarce 
 There is a need for PROMs that cover vulva cancer-related morbidity   
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Introduction   
The surgical treatment of vulvar cancer (VC) has changed dramatically in the last few decades towards a 
less radical approach.  The standard treatment for small tumors (< 4 cm) is wide local excision (WLE) 
combined with sentinel lymph node biopsy (SLNB) and vulvectomy with inguinal lymph node dissection 
(ILND) for larger tumors or sentinel node (SN) metastases [1-3] . In the case of metastatic lymph nodes in 
the groin, adjuvant radiation therapy (RT) improves survival [4]. Primary or neoadjuvant chemo radiation 
(CRT) is considered in locally advanced unresectable tumors involving the urethra or anus [5-7]. Despite the 
less radical surgery to the vulva and groin, multimodality treatment is mutilating and associated with a high 
risk of short- and long-term consequences that may interfere with the quality of life (QoL) [8-14] .  Several 
aspects of treatment options are being investigated and issues related to radicality of surgery and 
radiotherapy are still unresolved. The patient perspective is important when evaluating treatment effects. 
Patient-reported outcome measures (PROMs) complements clinical data with the patient’s perspective and 
there is an increasing demand for systematic implementation of PROMs in daily clinical practice and clinical 
trials [15] . It has therefore become important to develop PROMs that allow broad cross-cultural 
application.  
The aim of the present study was to evaluate disease- and treatment- related effects as measured by 
PROMs in VC patients.  Further, to identify available VC-specific PROMs with the overall purpose of 
assessing the need for developing a new questionnaire module which specifically focuses on the 
consequences of VC treatment. This systematic review was performed as part of the first of four phases in 
the development of a new questionnaire module for QoL assessment in VC patients, alongside the  
European Organisation for Research and Treatment of Cancer  Quality  of Life Core Questionnaire (EORTC 
QLQ-C30) [16].  
 
Material and Methods 
 
The present systematic review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses  (PRISMA) statement [17]. The population included women 
undergoing surgery and/or CRT for primary or recurrent VC. The primary outcome was VC-specific PROMs, 
which were not covered by generic questionnaires. Furthermore, studies were excluded if they included 
fewer than 20 patients or involved patients with vulvar intraepithelial lesions (VIN) or non-vulvar 
gynecological cancer patients only, unless results for a VC subgroup were reported separately.  We also 
excluded studies evaluating late effects after “en bloc” vulvectomy since this procedure has been replaced 
by individualized surgery. Finally, papers reporting on acute or late effects as rated by health care 
professionals, surgical guidelines, case reports, letters to the editor, or reviews were excluded.  
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Literature Search  
 
The search was conducted by one author (LPF) in collaboration with an information specialist at 
Copenhagen University Library. The PubMed, Embase, the Cochrane Library, CINAHL and psychINFO was 
searched for articles reported in English and published since 1990 using the following search string: 
("Vulvar Neoplasms") OR ((Vulva*) AND (Neoplasm* OR Cancer* OR Tumor* OR Tumour* OR Malign* OR 
Carcinom*)) AND (("Sexual Dysfunction]) OR ("Quality of Life") OR "Complications" OR "Morbidity" OR 
"Lymphedema" OR "Body Image OR "Proctitis" OR "Urology" OR "Groin")). In PubMed, all search terms 
were coined as MESH terms and as Title/ abstract ensuring the capture of articles that had not yet been 
indexed. No constraints related to publication type were applied. The primary search was performed on 
April 1st 2011 as the initial step in developing an EORTC QoL questionnaire for VC. The search was updated 
on February 5th 2016 for the present systematic review. 
 
Study selection and data collection  
 
The titles of all studies were reviewed by two authors (LPF, PTJ). If both authors agreed, studies were 
included/excluded. Disagreements were resolved by consensus.  Reference lists of identified articles were 
reviewed. Subsequently, all potentially included papers were further screened by abstract by both authors. 
The study selection process is shown in Figure 1.  
 
Results  
 
Literature search and study selection  
 
Eleven original studies were selected through a step-wise exclusion (Figure 1) from the 2299 studies initially 
identified in the search. No randomized controlled trials were identified. The characteristics of the included 
studies are shown in Table 1. The studies comprised 535 cases of VC. The patients’ age ranged from 24 to 
98 years. Four of the studies included patients who had recurrent disease. In general, all studies were small, 
with fewer than 100 patients included. The methodological quality of the studies is summarized in Table 2.  
 
 
Questionnaires used  
 
In the included studies, 21 different questionnaires were used to assess QoL (Table 2). Seven studies used 
cancer-specific generic questionnaires: EORTC QLQ- C30, The Functional Assessment of Cancer Therapy — 
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General (FACT- G) and the Utility-Based Questionnaire Cancer (UBQ-C)) [18-20].  One non- cancer specific 
generic QoL instrument, the Medical Outcomes Study Short Form SF Health survey – (SF-36 and SF-12), was 
used in three studies (Table 2) [21]. All of the included generic questionnaires have been validated and used 
in different patient populations and will not be further commented upon. 
In seven of the studies, non-vulva-specific questionnaires were used to assess disease- and treatment-
related outcomes in VC patients:  the EORTC QLQ Cervical Cancer Module (CX24), the Female Sexual 
Function Index (FSFI), the Electronic Pelvic Floor Assessment Questionnaire (ePAC-PF), the International 
Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and the Body Image Scale (BIS) (Table 3) 
[22-26]. One VC-specific QoL questionnaire was identified [27]. The Functional Assessment of Cancer 
Therapy Vulva (FACT-V) consists of 15 single items assessing different aspects of patients’ concerns [28].  
 
Vulva cancer-specific effects and QoL issues 
 
Vulva-specific symptoms 
 
Vulva-specific symptoms were assessed in two studies [27, 29]  by FACT-V (Table 2 and 3). In the study by 
Oonk et al. no differences in vulva-specific symptoms (discharge/blood loss, odor, itching and 
pain/numbness) were identified between patients treated with SLNB compared to ILND [29]. The majority 
of patients (94%) included in this study received WLE. They reported on subscale level for the vulva 
symptoms [29] although no scale structure was given in the paper on validation of the FACT-V [27].  In the 
study by Janda et al., patients treated for recurrent disease (eight of 97 patients) had a significantly lower 
FACT-V summary score (p= 0.03), indicating a worse QoL and a higher level of symptoms compared to 
patients with primary disease [27]. However, all symptoms were summarized in one scale score [27].  When 
assessing patients longitudinally (20 patients) within the same study, symptoms related to the vulva 
(discharge/bleeding, odor, itching/burning) improved at two months post-surgery as compared to baseline 
[27]. 
 
Sexual function (SXF) 
 
Different aspects of SXF were evaluated in all the included studies by either self-designed non-validated 
questionnaires  [30-33], the FSFI [34-36]; the sexual function scale, or by sexual single items of the EORTC 
QLQ- CX24 and the general sex life domain of the e-PAQ-PF [37, 38] (Table 2 and 3). Two studies used the 
FACT-V questionnaire (Table 2 and 3), but for 15 items of very different issues only summary scores were 
given; no scores on SXF or vaginal problems were presented [27, 29] .   
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Information on sexual activity (yes or no) was given in eight studies and varied between 8 and 61% with 
baseline data available in three studies [29-35, 37]. Only half of the sexually active women regained sexual 
activity within six months after surgery [30, 31]. Gunther et al. found decreased sexual activity in women 
treated with vulvectomy compared to women treated with WLE (16% vs. 43%) [32], whereas three other 
studies assessing changes in sexual activity over time and across surgical methods  were not able to detect 
differences regardless of the questionnaire used (FACT-V, FSFI, EORTC QLQ- CX24) (Table 2-3) [29, 34, 37]. 
Two studies identified significantly decreased desire and arousal [30], and more problems with dyspareunia 
and ability to achieve orgasm in VC patients compared to healthy control women [31], using self-designed 
non-validated questionnaires (Table 2). Significant deterioration of general SXF over time before and after 
the treatment in VC patients was reported in two studies, assessed by self-designed non-validated 
questionnaire and the general sex life domain of the e-PAQ-PF (Table 2-3)  [30, 39].Furthermore, in one 
study adjuvant inguinal RT was negatively associated with the ability to achieve orgasm (p= 0.01) [34].  
Factors associated with post-treatment sexual dysfunction included ILND [36], older age [30, 34-36] poor 
performance status, a history of depression and preoperative psychosexual difficulties [30].  
 
Body image  
 
Body image (BI) was assessed in five studies [27, 29, 30, 34, 37] by four questionnaires (FACT-V, EORTC QLQ 
CX-24, BIS and a self-designed questionnaire) (Table2 and 3). In the study by Green et al., women after 
vulvectomy were questioned  on BI disturbances prior to surgery and three months post-treatment using a 
self-designed questionnaire (five items on BI) [30].  A significant worsening in BI after surgery compared to 
baseline was reported (p= 0.004) [30]. In the study by Novackova et al., women had  a significantly worse BI 
after vulvectomy and ILND as compared to women who had WLE and SLNB  (p=0.033) at 12 months follow-
up as measured by the BI sum-score of the EORTC QLQ CX24 [37]. In contrast, two studies, using the FACT-V 
and BIS questionnaire, did not find any difference in BI between patients treated with ILND or SLNB [29, 
34].  
 
Lymphedema 
 
Lower limb lymphedema(LLL) was assessed in six studies [27, 29, 32, 33, 35, 37] by self-designed non-
validated questionnaires [32, 33];  single item in the FACT-V [27, 29]; and Miller´s Clinical Evaluation of 
Lymphedema and  the lymphedema scale of the EORTC QLQ- CX24 [34] (Table 2 and 3). 
Overall, a high incidence of LLL after ILND as compared to a healthy control group was reported (in two 
studies 68- 73% vs. 11%) (p< 0.001) [33, 35]. Additionally, leg pain and cellulitis were experienced by 53% and 
23% of the patients, respectively [33]. In line with these findings, Oonk et al. reported that patients who 
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underwent ILND had more discomfort in the groin, vulva and legs (p= 0.03), resulting in a greater need to 
wear stockings (p=0.003) as compared to the SLNB group [29]. Oonk et al. used the FACT-V questionnaire 
supplemented with additional non-validated items [29]. Novackova et al. observed that LLL after ILND 
persisted with no signs of improvement at six and 12 months follow-up (p= 0.046 and p= 0.028) [37]. 
Moreover, LLL was significantly negatively associated with most of the EORTC QLQ- C30 domains (physical, 
cognitive, emotional and social function, fatigue, pain, sleep, and financial impact) (p< 0.05) indicating worse 
QoL [33, 35, 37] in addition to  lower BI (p= 0.003) [37] and worse SXF [33]. 
 
Urinary function  
 
Urinary function was assessed in five studies [27, 29, 35, 37, 38] by four questionnaires (FACT-V- to items 
and  EORTC QLQ CX-24, ePAC-PF and ICIQ-SF- four items each on urinary function) (Table 2 and  3). The 
FACT-V and the EORTC CX-24 included urinary items in a common summary score. Novackova et al. did not 
find any difference in Symptom Experience Scale score between patients treated by extensive versus less 
extensive surgery using the EORTC CX24. Furthermore, no difference was observed at six and 12 months 
follow-up as compared to the base line level [37].  In line with this, de Melo Ferreira et al. did not find any 
difference in urinary incontinence between VC patients (28 patients) treated with vulvectomy and ILND and 
healthy controls [35].   
 
Bowel function  
 
Assessment of bowel function was included in six studies [27, 29, 32, 35, 37, 38] and four questionnaires 
(EORTC QLQ C30, EORTC QLQ- CX 24, FACT-V, and ePAQ-PF) were used (Table 2 and 3). In the study by 
Gunther et al., diarrhea was more commonly reported in patients treated with vulvectomy compared to 
patients treated with WLE [32]. In the study by Novackova et al. patients who received adjuvant RT to the 
groin in addition to ILND (13 patients) had a higher score on the Symptom Experience Scale from the EORTC 
CX-24, indicating more symptoms (p= 0.05) at six and 12 months as compared to patients who were not given 
adjuvant RT (11 patients) [37]. It should be noted that reporting on scale level for the Symptom Experience 
Scale does not provide any knowledge regarding the origin of symptoms (urinary, bowel, pain or 
vulva/vaginal), and individual symptom scores were not reported [37].  
 
Discussion 
 
To our knowledge, this systematic review is the first to evaluate available PROMs for use in patients with 
VC. The review was performed to explore the need for development of a VC-specific PROM. Overall, the 
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literature review supports the clinical impression that treatment of VC is associated with long-term 
consequences within several domains of the patient’s well-being. However, the conclusions are vague and 
probably fail to include symptoms and issues of importance for this particular patient group. The reporting 
of late effects exhibits great heterogeneity between studies, probably reflecting the lack of a PROM with 
robust and sensitive scales. Thus, the present study supports the necessity of developing a VC-specific 
PROM to evaluate disease- and treatment-specific domains in VC patients undergoing different treatment 
modalities.  
 
Despite wide inclusion criteria, only 11 studies were identified as eligible and most of the studies used 
PROMs that were either generic, non-vulva cancer-specific, or developed for other cancer diagnoses. We 
identified only one study, which used a VC- specific PROM- FACT-V [27, 28]. The measure has no scale 
structure but is suggested to be summarized as one sum-score although conceptually very different 
domains are being assessed and the sensitivity of the measured concepts is therefore doubtful. The 
psychometric properties have been tested in a comparatively small sample of Australian patients only (20 
patients for test-retest analyses and additionally 77 patients for the validity analyses, of whom only eight 
had received adjuvant radiotherapy) [27, 28].  Conceptual scale problems and the fact that reliability and 
validity have been assessed in only one country in a very limited population, preclude broad cross-cultural 
adaptation. For international multi-center studies it would be valuable if a balanced patient sample, 
representing different cultures and languages is included in the development and validation phases. 
 
Several areas of potential importance to VC patients were identified. Results for SXF and BI seem to be 
conflicting. However, the inconsistencies may be attributed to the lack of power due to the small study size 
and the low percentage of sexually active patients. The well-known reluctance among elderly patients in 
particular to respond to intimate questions, and their minor concern about body image might explain this 
observation to some point [29, 34, 35, 37]. Furthermore, only half of the included studies reported data on 
partner status. Finally, the instruments for assessment of SXF in VC patients used in the included studies 
were generally non-validated, self-designed, or validated in healthy women or cervical cancer patients. 
None of the questionnaires assessed potential vulvo-vaginal problems such as narrowing of the vaginal 
entrance or swelling of the genital area that may interfere with SXF after VC treatment.   The outcomes of 
the studies in regard to SXF were predominantly sexual activity (yes or no) and an overall female sexual 
dysfunction total score, which may not properly reflect vulva cancer patients’ SXF.  The present review 
indicates that despite less extensive and more individualized surgery to the vulva and groin, SXF and BI are 
likely to deteriorate, especially among patients who have had ILND and/or adjuvant RT. These findings need 
confirmation in high quality longitudinal studies including patient-reported vulva-specific outcomes.  
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Lower limb lymphedema is a disabling complication affecting women with VC after surgery and adjuvant RT 
of the groin [40-42]. In the present review the incidence of  LLL in two studies was approximately 70%, 
which was substantially higher than in the results of previous studies reporting LLL rates between 14 and 
48% [42]. It is well known that the incidence of LLL is higher when subjectively assessed using PROMs as 
compared to using data obtained from medical records [43].  The present review suggests that LLL has a 
significant negative impact on the QoL following treatment of VC and that LLL may be associated with 
sexual life disruption, lower physical functioning, and decrease in social activities [33, 35].  The focus in 
most included studies seemed to be assessment of LLL only. However, retrospective studies not involving 
PROMs have indicated that lymphedema of the groin and the vulva region also appear to be of great 
importance for the QoL of VC patients [11]. Therefore, lymphedema of the groin and the vulva should be 
covered in a future comprehensive assessment of lymphedema in VC patients following treatment. 
 
Less attention has been paid to urinary, bowel and vulva symptoms following VC treatment. Though these 
symptoms were assessed in several included studies, the individual scores on urinary, bowel, and vulva 
symptoms were not provided, but rather included in the Symptom Experience Scale (EORTC CX-24) or in 
the Vulvar Cancer-Specific Subscale (FACT-V) [29, 37].  Several studies on gynecological cancer indicate that 
severe late effects related to both the small and large intestine, bladder, vagina and vulva are prevalent 
following pelvic RT [13, 33, 44-46]. Due to small sample sizes in the studies included in the review, the 
impact of CRT on the VC patient’s QoL cannot be validly evaluated.  
 
In conclusion, vulva cancer treatment is associated with considerable morbidity and deteriorating QoL. To 
date there is no validated PROM available that provides adequate coverage of VC-related issues. The study 
confirms the need for a VC-specific QoL instrument with sensitive scales that allows broad cross-cultural 
application. Based on the findings of this review the EORTC quality of life group is currently developing such 
a PROM to supplement the generic QLQ-C30 with disease- and treatment-specific QoL dimensions for use 
in cancer clinical trials of VC patients.  
 
  
  
10 
 
Conflict of interest statement 
None declared 
 
Acknowledgements 
This work was funded by the EORTC Quality of life group (QLG). The Gynecological Cancer group within the 
EORTC is acknowledged for their participation in the review process.  
 
  
  
11 
 
Legends of Tables and Figures 
 
Figure 1: Flowchart for study selection (PRISMA) 
 
Table 1: Demographic and patient characteristics of the included studies 
Table 2: Study characteristics  
Table 3: Patient-reported quality of life instruments used to assess vulva-specific symptoms 
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